MarkBoguniewiczMD
Allergy & Immunology • Denver, COAsthma & Allergic Conditions
Professor, Pediatrics, University of Colorado School of Medicine
Dr. Boguniewicz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1400 Jackson St
Denver, CO 80206Phone+1 303-388-4461Fax+1 303-270-2206
Education & Training
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1986 - 1989- Boston Children’s HospitalFellowship, Allergy and Immunology, 1985 - 1988
Medical University of WarsawClass of 1982
Certifications & Licensure
CO State Medical License 1990 - 2025
MI State Medical License 1983 - 1994
American Board of Allergy and Immunology Allergy & Immunology
American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Distinguished Clinician Award American Academy of Allergy, Asthma and Immunology, 2013
- Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
Publications & Presentations
PubMed
- CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity.H Mark Kenney, Takeshi Yoshida, Evgeny Berdyshev, Agustin Calatroni, Steven R Gill
The Journal of Allergy and Clinical Immunology. 2025-02-01 - Corrigendum to 'A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American...Jay A Lieberman, Derek K Chu, Tasnuva Ahmed, Timothy E Dribin, Elissa M Abrams
Annals of Allergy, Asthma & Immunology. 2025-02-01 - 1 citationsDupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis.Lisa A Beck, Antonella Muraro, Mark Boguniewicz, Zhen Chen, Joseph Zahn
The Journal of Allergy and Clinical Immunology. 2025-01-01
Journal Articles
- Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their FamiliesJonathan I Silverberg, Amy S Paller, Mark Boguniewicz, Sarah L Chamlin, Eric L Simpson, Lawrence F Eichenfield, Steven R Feldman, Dermatology and Therapy
Press Mentions
Dupilumab Effective for Atopic Dermatitis in Young Children with, Without ComorbiditiesDecember 16th, 2024- Dupilumab Efficacious for Atopic Dermatitis in Young ChildrenDecember 11th, 2024
- Research Shows Medication Effective in Treatment of Children with Atopic DermatitisDecember 4th, 2024
- Join now to see all
Grant Support
- Atopic Dermatitis Research NetworkNIHPresent
Professional Memberships
- Fellow
- American College of Allergy, Asthma and ImmunologyFellow
Other Languages
- Polish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
